Primer Karaciğer Tümörlerinde Radyoterapinin Yeri
Özet
Primer karaciğer kanserleri arasında en sık görülen tür hepatoselüler karsinomdur (HCC). Cerrahi müdahale küratif bir tedavi seçeneği sunsa da hastaların büyük bir kısmı tanı anında inoperabl durumdadır. Bu durum, cerrahiye alternatif olarak geliştirilen lokal ablatif tedavilerin ve stereotaktik radyoterapinin (SBRT) önemini artırmaktadır. Son yirmi yılda görüntüleme ve tedavi planlama sistemlerinde yaşanan teknolojik gelişmeler, SBRT'nin normal doku komplikasyon riskini minimuma indirerek tümör kontrolünde yüksek biyolojik eşdeğer dozlar sunmasını sağlamıştır. Yapılan klinik çalışmalar, SBRT'nin özellikle erken ve orta evre HCC hastalarında yüksek lokal kontrol ve sağkalım oranları elde ettiğini göstermektedir. Ayrıca, Transarteriyel Kemoembolizasyon (TACE) ile radyoterapi kombinasyonları veya proton/karbon iyonu gibi parçacık radyoterapileri de ileri evre hastalar için umut verici sonuçlar sunmaktadır. Bununla birlikte, tedavi başarısını optimize etmek ve karaciğer toksisitesini önlemek adına hasta bazında multidisipliner değerlendirmeler kritik bir rol oynamaktadır.
Hepatocellular carcinoma (HCC) is the most prevalent type of primary liver cancer. Although surgical resection offers a curative treatment pathway, a significant majority of patients are deemed inoperable at the time of diagnosis due to poor liver function or tumor characteristics. Consequently, advanced localized therapies and stereotactic body radiation therapy (SBRT) have emerged as crucial alternatives. Technological advancements over the past two decades in imaging and treatment planning systems have enabled SBRT to deliver highly effective biological doses while minimizing the risk of radiation-induced liver disease and surrounding tissue toxicity. Clinical studies demonstrate that SBRT provides excellent local control and survival rates, particularly for early and intermediate-stage patients. Furthermore, combining transarterial chemoembolization (TACE) with radiation therapy, or utilizing particle therapies like proton and carbon ion radiation, shows promising efficacy for advanced cases. Ultimately, a patient-specific multidisciplinary evaluation remains vital to safely navigating liver reserves and optimizing therapeutic outcomes.
Referanslar
Global Cancer Observatory [Internet]. [cited 2021 Oct 30]. Available from: https://gco.iarc.fr/
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2012 Dec 15;380(9859):2095–128.
Bosman: Sindirim sistemi tümörlerinin WHO sınıflandırması... - Google Akademik [Internet]. [cited 2021 Oct 16]. Available from: https://scholar.google.com/scholar_lookup?title=WHO%20classification%20of%20tumours%20of%20the%20digestive%20system&author=World%20Health%20Organization&publication_year=2010
Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Primer. 2016 Apr 14;2:16018.
Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010 Feb;30(1):61–74.
European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012 Apr;56(4):908–43.
Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatol Baltim Md. 2000 Dec;32(6):1224–9.
Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009 Jan;10(1):35–43.
Schwarz RE, Smith DD. Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population. Am J Surg. 2008 Jun;195(6):829–36.
Buscarini L, Buscarini E, Di Stasi M, Vallisa D, Quaretti P, Rocca A. Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur Radiol. 2001;11(6):914–21.
Waki K, Aikata H, Katamura Y, Kawaoka T, Takaki S, Hiramatsu A, et al. Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: results and prognostic factors on long-term follow up. J Gastroenterol Hepatol. 2010 Mar;25(3):597–604.
Chinnaratha MA, Chuang MA, Fraser RJL, Woodman RJ, Wigg AJ. Percutaneous thermal ablation for primary hepatocellular carcinoma: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2016 Feb;31(2):294–301.
Huertas A, Baumann A-S, Saunier-Kubs F, Salleron J, Oldrini G, Croisé-Laurent V, et al. Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2015 May;115(2):211–6.
Kimura T, Aikata H, Takahashi S, Takahashi I, Nishibuchi I, Doi Y, et al. Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies. Hepatol Res Off J Jpn Soc Hepatol. 2015 Apr;45(4):378–86.
Lo C-M, Ngan H, Tso W-K, Liu C-L, Lam C-M, Poon RT-P, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatol Baltim Md. 2002 May;35(5):1164–71.
Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet Lond Engl. 2002 May 18;359(9319):1734–9.
Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther. 2009 Jun;9(6):739–45.
Yoon SM, Ryoo B-Y, Lee SJ, Kim JH, Shin JH, An JH, et al. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. JAMA Oncol. 2018 May 1;4(5):661–9.
Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RKS, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2013 May 1;31(13):1631–9.
Soliman H, Ringash J, Jiang H, Singh K, Kim J, Dinniwell R, et al. Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases. J Clin Oncol Off J Am Soc Clin Oncol. 2013 Nov 1;31(31):3980–6.
Canadian Cancer Trials Group. Phase III Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases [Internet]. clinicaltrials.gov; 2021 Oct [cited 2021 Oct 14]. Report No.: NCT02511522. Available from: https://clinicaltrials.gov/ct2/show/NCT02511522
Sanuki N, Takeda A, Oku Y, Mizuno T, Aoki Y, Eriguchi T, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol Stockh Swed. 2014 Mar;53(3):399–404.
Blomgren H, Lax I, Näslund I, Svanström R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol Stockh Swed. 1995;34(6):861–70.
Méndez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJM, Nowak PCJM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol Stockh Swed. 2006;45(7):831–7.
Takeda A, Sanuki N, Tsurugai Y, Iwabuchi S, Matsunaga K, Ebinuma H, et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer. 2016 Jul 1;122(13):2041–9.
Culleton S, Jiang H, Haddad CR, Kim J, Brierley J, Brade A, et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2014 Jun;111(3):412–7.
Hollebecque A, Cattan S, Romano O, Sergent G, Mourad A, Louvet A, et al. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Aliment Pharmacol Ther. 2011 Nov;34(10):1193–201.
Huo YR, Eslick GD. Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncol. 2015 Sep;1(6):756–65.
Brade AM, Ng S, Brierley J, Kim J, Dinniwell R, Ringash J, et al. Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):580–7.
Radiation Therapy Oncology Group. Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma [Internet]. clinicaltrials.gov; 2021 Mar [cited 2021 Oct 17]. Report No.: NCT01730937. Available from: https://clinicaltrials.gov/ct2/show/NCT01730937
Samuel M, Chow PK-H, Chan Shih-Yen E, Machin D, Soo K-C. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD001199.
Rajyaguru DJ, Borgert AJ, Smith AL, Thomes RM, Conway PD, Halfdanarson TR, et al. Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database. J Clin Oncol Off J Am Soc Clin Oncol. 2018 Feb 20;36(6):600–8.
Fukumitsu N, Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Abei M, et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):831–6.
Bush DA, Kayali Z, Grove R, Slater JD. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer. 2011 Jul 1;117(13):3053–9.
Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, et al. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2016 Feb 10;34(5):460–8.
Kasuya G, Kato H, Yasuda S, Tsuji H, Yamada S, Haruyama Y, et al. Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials. Cancer. 2017 Oct 15;123(20):3955–65.
